At a meeting of the Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee, the majority of panel members voted against the approval of sotagliflozin (Zynquista™) ...

Hybrid closed-loop insulin therapy prevents low night-time blood glucose levels among breastfeeding mothers with type 1 ...

Revolutionary glucose-responsive insulin NNC2215 offers hope for diabetics, managing blood sugar levels without hypoglycemia ...

Type 1 diabetes in China has successfully undergone a stem-cell therapy that enabled her to produce her own insulin, reducing ...

Marlaina Goedel, diagnosed at age 5, said she is no longer on insulin. For Dr. Daniel Gilada, a husband, physician and soon-to-be father of four, living with Type 1 diabetes had become “overwhelming.” ...

Early morning hyperglycemia is sometimes called the “dawn phenomenon.” Left untreated, it can drive poorer outcomes. How can ...

Early research shows the CD40L antibody tegoprubart is able to reduce insulin dependence in patients with type 1 diabetes after islet transplants.

Insulcloud today announced its strategic expansion into the U.S. following FDA clearance for its Insulclock CAP smart device.

“These results support the continued investigation of intranasal insulin and empagliflozin combination therapy for AD,” they ...

Our increase in customers coming from MDI is an important shift that we anticipate will continue as our portfolio attracts more people to insulin pump therapy. We also continue to see customer ...

An FDA advisory committee voted Thursday that it didn’t believe the benefits of Lexicon's (LXRX) diabetes drug sotagliflozin ...